SAT0310 The associations of serum il18 and osteoprotegerin (OPG) levels with the lipid profile in psoriatic arthritis (PSA) patients

Background We have previously found that IL-18 and OPG serum concentrations are correlated with cardiovascular (CV) risk in psoriatic arthritis but not in ankylosing spondylitis (AS) patients.1 Objectives To investigate whether in PsA patients the association of OPG and IL-18 with CV risk is mediated by an impact of these cytokines on lipid profile changes. Methods 49 patients with PsA (25 M/24 F) with (n=10) and without (n=39) coronary heart disease (CHD), and 25 sex and age matched (mean age 44,4 vs 43,4 years) patients with AS were enrolled. Disease activity was measured by DAPSA (25,17±19,9) in PsA group and by BASDAI (5,37±2) and ASDAS- CRP (3,18±1) in AS group. The lipid profile (triglycerides – TG, total cholesterol – tChol, low- and high-density lipoprotein – LDL and HDL, respectively), systemic inflammation markers and cytokines (OPG, IL-18) were measured in patients serum samples. Atherogenic index (AI=tChol/HDL) was calculated. Statistical analysis was performed using Mann-Whitney U-test and Spearman’s Rank test. Data are expressed as mean values. Results Patients with PsA presented more atherogenic lipid profile than AS patients because of their higher TG levels (153 vs 126,6 mg/dl; p=0,05) and AI values (3,83 vs 3,24; p=0,05) while lower HDL concentrations (51,6 vs 61,4 mg/dl; p=0,04). Compared to AS group, PsA patients were characterised by higher IL-18 (235 vs 208 pg/ml; p Conclusions We report that in PsA, but not AS, patients serum IL-18 and OPG concentrations are correlated with an altered and pro-atherogenic lipid profile. These associations are stronger in patients with concomitant CHD. Thus, present results explain partially the way by which these cytokine contribute to CV complications in PsA. Reference [1] Kontny E, et al. Association of serum osteoprotegerin and IL-18 concentrations with cardiovascular risk in ankylosing spondylitis and psoriatic arthritis. Ann Rheum Dis2017;76(suppl 2):1310–1311AB0733. Disclosure of Interest None declared